With a WTP threshold of $100,000/QALY, the first line monotherapy studies have shown the cost-effectiveness of the therapy in melanoma (nivolumab/pembrolizumab vs. dacarbazine/ipilimumab [142,143,144,145]) and in NSCLC PD-L1 ≥50% (pembrolizumab vs. chemotherapy [146]). Here, CD274 is linked to melanoma.